| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1dfd39878009ed672c93ba0247ee666 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2000-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd1d3f110b664c243cbbaee77d798463
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4972ce7afa0d94165593c087ad66e257
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_449ea2417170c7c60c1aa6a64e58d9ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0696b6ec30907d2de133c6f92a60ad6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e11886b2aa5c95780654516e770c69d2 |
| publicationDate |
2002-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6468990-B1 |
| titleOfInvention |
Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| abstract |
The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9789161-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009215815-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7579468-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006063793-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007253930-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7423039-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7291629-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005250807-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007021609-A1 |
| priorityDate |
1999-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |